Accent Microcell

Ahmedabad, India Founded: 2001 • Age: 25 yrs Listed
Microcrystalline cellulose and excipients are manufactured by Accent Microcell.
Request Access
Report Incorrect Data
Page last updated

About Accent Microcell

Accent Microcell is a publicly listed company based in Ahmedabad (India) founded in 2001. Microcrystalline cellulose and excipients are manufactured by Accent Microcell. Accent Microcell has raised $1.5 million across 1 funding round from investors including Adwaitartha, Vivinseccom and Swarnali Advisors. The company has 147 employees. Accent Microcell was last valued at $9.29 million in August 2023. Its chief executive, as recorded, is Manoj Patel. Its Indian entity Accent Microcell Limited reported revenue of ₹356 Cr. Accent Microcell offers products and services including Microcrystalline Cellulose (MCC) and Cosmetic Excipients. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Excipient Production.

Company details

Accent Microcell Ltd. was established in 2001 in Ahmedabad, India, within the pharmaceutical sector. Microcrystalline cellulose is produced as a thickening agent, along with other excipient and derivative products. Manufacturing processes are guided by principles of integrity, discipline, and commitment. Operations focus on supplying these materials for various pharmaceutical applications.

  • Headquarters Ahmedabad, India
  • Employees 147
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website accentmicrocell.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Accent Microcell Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹1,487 Cr

    ACCENTMIC-SM · NSE

  • Share Price
    ₹630.00

    +1.66% today

  • Revenue
    ₹349 Cr

    FY 2025-26 · +31.9% YoY

  • EBITDA
    ₹56.69 Cr

    Margin 16.2%

  • Net Profit
    ₹43.86 Cr

    FY 2025-26 · +32.7% YoY

  • P/E (TTM)
    35.0x

    P/B 5.6x

  • ROE
    18.6%

    ROCE 24.7%

  • Debt / Equity
    0.01

    Interest cover 1.0x

  • Total Equity Funding
    $1.5M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.5M (USD), Seed

    Aug 2023

  • Employee Count
    147

Products & Services of Accent Microcell

Accent Microcell offers a comprehensive portfolio of products and services, including Microcrystalline Cellulose (MCC) and Cosmetic Excipients.

Microcrystalline Cellulose (MCC)
Excipient

Used for drug delivery in pharmaceuticals and texture in food

Cosmetic Excipients
Personal Care Ingredients

Enhances smoothness and quality in cosmetics products

Funding Insights of Accent Microcell

Accent Microcell has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.5M
  • Total Rounds 1
  • Last Round Seed — $1.5M
  • First Round $1.5M

    (Aug 2023)

  • Investors Count 55

All 1 funding rounds of Accent Microcell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2023$1.5MSeed$9.29MAdwaitartha, Vivinseccom
Manoj Agarwal, Utsav Pramodkumar Shrivastav
Valuation history
DateValuationStage
Aug 2023$9.29M••••••••

Last known valuation $9.29M (Aug 2023). 55 investors in total: 3 institutional and 52 angel.

Investors in Accent Microcell

Accent Microcell has secured backing from 55 investors, including institutional and angel investors. Prominent investors backing the company include Adwaitartha, Vivinseccom and Swarnali Advisors.

All
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Adwaitartha
Vivinseccom

Manoj Agarwal

Co-founder of Innov8, active angel investor in Indian startups
unknown_7b0f9d79b60747869

Utsav Pramodkumar Shrivastav

unknown_fd95867b722342c89

Manish Kumar Garg

unknown_18102fb6fc1f49b08

Jagdish Prasad Sharma

unknown_65814bdec26d44d7b

Kadayam Ramanathan Bharat

unknown_cfc5b49e4b4942b2a

Parmar Gordhanbhai

unknown_13c3bac827b041b99

Payal Tandan Shrivastava

unknown_ce4a2dcaa9a348d3a

Preeti Garg

unknown_9df5e94ea52f4e9d8
Premium access

Investor details for Accent Microcell

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Accent Microcell Limited (Accent Microcell)

Accent Microcell Limited is the primary company behind Accent Microcell. The board of Accent Microcell Limited currently have 7 directors; the longest-serving is Ghanshyam Arjanbhai Patel, appointed in 2012. 7 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ghanshyam Arjanbhai Patel
DIN 05225398
Managing Director10 Apr 201214 yrs 6 moAccent Microcell Limited
Nitin Jasvantbhai Patel
DIN 05225550
Whole-time director10 Apr 201214 yrs 6 moAccent Microcell Limited
Vasant Vadilal Patel
DIN 05225561
Whole-time director10 Apr 201214 yrs 6 moAccent Microcell Limited
Vinodbhai Manibhai Patel
DIN 07698117
Whole-time director03 Jan 20179 yrs 9 moAccent Microcell Limited
Rajatkumar Dineshbhai Patel
DIN 09124295
Director05 May 20233 yrs 5 moAccent Microcell Limited
Shreyaben Milankumar Shah
DIN 09726000
Director18 Aug 20233 yrs 2 moAccent Microcell Limited
Pooja Dharmesh Shah
DIN 10851564
Director06 Jul 20263 moAccent Microcell Limited

People of Accent Microcell

8 people are tracked at Accent Microcell (2 in leadership, 6 in team); the tracked headcount is 147.

NameRoleGroup
Ghanshyam Arjanbhai Patel
Managing Director & CFOLeadership
Manoj Patel
CEOLeadership
Sunil Kumar Panigrahi
Manager Quality Assurance And Regulatory AffairsTeam
Mihir Panchal
ExecutiveTeam
Rakesh Christian Gmail
Manager EximTeam
Aditya Yadav
Senior Executive International Business At Accent MicrocellTeam
MacHhi Mahesh
Human Resources OfficerTeam
Zeel Chauhan
Purchase ExecutiveTeam
Premium access

Complete people profiles for Accent Microcell

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Accent Microcell

Accent Microcell is a publicly listed company on the NSE with ticker symbol ACCENTMIC in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Dec 2023
  • Listed onNSE: ACCENTMIC
  • Listed entityAccent Microcell Limited
  • Exchange sectorHealth technology
  • ISININE0Q5D01013
  • Share price₹695.85 (+2.58% on the day) · 2026-10-14
  • Market capitalisation₹1,627 Cr
  • Price to earnings37.6
  • EPS (diluted, trailing year)₹18.53
  • Dividend yield0.15%
  • Volume (last session)212,500

Financials of Accent Microcell

Exchange-reported figures of Accent Microcell Limited, the listed company behind Accent Microcell (NSE: ACCENTMIC-SM).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹349 Cr
+31.9% YoY
EBITDA
₹56.69 Cr
+35.3% YoY
Profit After Tax
₹43.86 Cr
+32.7% YoY
Net Worth
₹275 Cr
+41.4% YoY
Total Assets
₹279 Cr
+40.9% YoY
Total Debt
₹0.87 Cr
-42.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue349265246197166133131
Revenue growth+31.9%+7.8%+24.5%+19.1%+25.0%+0.9%-
EBITDA56.6941.9138.4718.9412.9810.698.79
EBITDA margin+16.2%+15.8%+15.7%+9.6%+7.8%+8.1%+6.7%
Profit before tax58.2643.7636.5214.797.596.016.07
Net profit43.8633.0630.9912.225.895.034.19
Net profit margin+12.6%+12.5%+12.6%+6.2%+3.6%+3.8%+3.2%
EPS (₹)18.2815.7114.349.454.5711.179.71
Balance sheet
Total assets27919817773.4756.6157.5255.03
Net worth27519516450.4232.0926.6325.10
Total debt0.871.5112.7922.8124.1030.6429.93
Cash & bank20.1051.0272.492.052.831.403.62
Net working capital11212513741.2727.1627.7727.42
Cash flow
Cash from operations18.6424.6711.337.5714.875.045.28
Cash from investing(48.88)(8.61)(82.34)(4.04)(4.30)(6.27)(1.97)
Cash from financing35.75(13.70)72.27(4.32)(9.67)(2.19)(2.35)
ParticularsMar 2023
Revenue58.81
Other income1.12
Total expenses50.09
EBITDA8.72
EBITDA margin+14.8%
Depreciation1.02
Interest0.53
Profit before tax8.29
Tax1.23

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 03 Nov 2026
ParticularsMar 2023
Revenue58.81
Other income1.12
Total expenses50.09
EBITDA8.72
EBITDA margin+14.8%
Depreciation1.02
Interest0.53
Profit before tax8.29
Tax1.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue349265246197166133131
Revenue growth+31.9%+7.8%+24.5%+19.1%+25.0%+0.9%-
Other income6.776.413.632.491.832.253.99
Total expenses292223207178153122123
Employee cost18.2115.4913.308.977.626.939.42
EBITDA56.6941.9138.4718.9412.9810.698.79
EBITDA margin+16.2%+15.8%+15.7%+9.6%+7.8%+8.1%+6.7%
Depreciation4.664.214.434.114.153.553.30
Interest0.540.351.152.533.073.383.41
Profit before tax58.2643.7636.5214.797.596.016.07
Tax14.4010.706.362.571.701.201.88
Net profit43.8633.0630.9912.225.895.034.19
Net profit margin+12.6%+12.5%+12.6%+6.2%+3.6%+3.8%+3.2%
EPS (₹)18.2815.7114.349.454.5711.179.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.9921.0421.0412.9412.904.304.30
Reserves & surplus25217414337.4819.1922.3320.80
Shareholders' funds (net worth)27519516450.4232.0926.6325.10
Secured loans1.392.1312.7719.8212.8517.0712.92
Unsecured loans(0.52)(0.62)0.022.9911.2513.5717.01
Total debt0.871.5112.7922.8124.1030.6429.93
Total liabilities27919817773.4756.6157.5255.03
Assets
Gross block93.7488.7765.6863.5258.5354.6649.51
Net block53.0147.9929.0431.3130.1130.3928.80
Capital work in progress10212.771.860.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories32.4133.6332.9841.9439.5931.5518.19
Sundry debtors91.3064.8753.8030.3517.0412.6121.56
Cash & bank balances20.1051.0272.492.052.831.403.62
Loans & advances11.134.844.163.274.464.194.52
Total current assets15515416377.6163.9249.7547.89
Total current liabilities43.0129.7426.5636.3436.7621.9820.47
Net working capital11212513741.2727.1627.7727.42
Total assets27919817773.4756.6157.5255.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.941.580.311.100.203.622.66
Net cash from operating activities18.6424.6711.337.5714.875.045.28
Net cash from investing activities(48.88)(8.61)(82.34)(4.04)(4.30)(6.27)(1.97)
Net cash from financing activities35.75(13.70)72.27(4.32)(9.67)(2.19)(2.35)
Net change in cash5.512.371.26(0.79)0.90(3.42)0.95
Closing cash20.1051.0272.492.052.831.403.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.9%+7.8%+24.5%+19.1%+25.0%+0.9%-
EBITDA growth+35.3%+8.9%+103.1%+45.9%+21.4%+21.6%-
PBT growth+33.1%+19.8%+146.9%+94.9%+26.3%-1.0%+27.3%
Net income growth+32.7%+6.7%+153.6%+107.5%+17.1%+20.1%-
Revenue CAGR (3Y)+21.0%+16.9%+22.8%+14.5%+13.3%--
EBITDA CAGR (3Y)+44.1%+47.8%+53.2%+29.2%+32.0%--
Profitability & leverage
Net income margin+12.6%+12.5%+12.3%+6.2%+3.6%+3.6%+3.2%
Return on capital employed+24.7%+23.5%+30.0%+26.7%+18.7%+16.7%+17.6%
Return on net worth+18.7%+18.4%+28.2%+29.6%+20.1%+18.6%+18.2%
Debt / equity0.010.040.170.570.931.171.34
Long-term debt / equity0.000.010.030.150.420.670.74
Interest cover1.040.933.3817.0634.7747.3462.11
Efficiency & per share
Fixed asset turnover3.823.433.803.232.932.552.71
Inventory turnover10.577.946.554.844.665.338.16
Debtors turnover4.474.465.838.3311.187.766.07
EPS (₹)18.2815.7114.349.454.5711.179.71
Dividend per share (₹)1.001.001.000.800.801.000.00
Book value per share (₹)114.8492.5777.8638.9624.8761.9258.36

Timeline of Accent Microcell

4 dated milestones of Accent Microcell across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Accent Microcell is founded.
  2. Funding First funding round of $1.5M.
  3. Milestone Reaches Minicorn status.
  4. IPO Lists on the stock exchange (IPO).

Web traffic of Accent Microcell

The website of Accent Microcell (accentmicrocell.com) receives about 1.4K visits a month.

  • Monthly visits
    1.4K

    ▼ 4.2% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Accent Microcell (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Accent Microcell

Accent Microcell Approves Capital Expenditure For 4.45 MW Wind Turbine Installation
Reuters • 2 months ago
Accent Microcell IPO allotment finalised: Latest GMP, steps to check Accent IPO allotment status
Livemint • 2 years ago
Accent Microcell Ipo Opens On December 8, Price Band Set At ₹133-140 Per Share
Livemint • 2 years ago
Premium access

Complete news archive for Accent Microcell

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Accent Microcell

Accent Microcell was founded in 2001 and raised its 1st funding round 22 years after it was founded.

Accent Microcell is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Manoj Patel is the CEO of Accent Microcell, as recorded in our data.

Accent Microcell is a funded company, having raised a total of $1.5M across 1 funding round to date. The company's 1st funding round was a Seed of $1.5M, raised on Aug 2023.

Accent Microcell has 147 employees.

The primary company behind Accent Microcell, Accent Microcell Limited, reported revenue of ₹356 Cr for FY 2026, up 32% year on year.

Accent Microcell Ltd. was established in 2001 in Ahmedabad, India, within the pharmaceutical sector. Microcrystalline cellulose is produced as a thickening agent, along with other excipient and derivative products. Manufacturing processes are guided by principles of integrity, discipline, and commitment. Operations focus on supplying these materials for various pharmaceutical applications.

Accent Microcell offers Microcrystalline Cellulose (MCC) and Cosmetic Excipients.

Yes, Accent Microcell is publicly traded on NSE under the ticker symbol ACCENTMIC.

Accent Microcell has 55 investors. Key investors include Adwaitartha, Vivinseccom, Swarnali Advisors, Manoj Agarwal, and Utsav Pramodkumar Shrivastav.

The valuation of Accent Microcell is $9.29M as of Aug 2023.

Accent Microcell operates through Accent Microcell Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available